Alpha 2.0
Login Register
» Authors » Jane Bryce

Jane Bryce

Explore the profile of Jane Bryce including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 972
Followers 0
Related Specialties
Oncology
Pharmacology
Critical Care
Top 10 Co-Authors
Francesco Perrone
Massimo Di Maio
Maria Carmela Piccirillo
Gennaro Daniele
Alessandro Morabito
Ciro Gallo
Gianfranco De Feo
Martin R Stockler
Stefania Scala
Jalid Sehouli
Published In
Support Care Cancer
Int J Gynecol Cancer
Gynecol Oncol
Expert Rev Anticancer Ther
BMJ Open
Affiliations
Soon will be listed here.
Recent Articles
1.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer
Roncolato F, King M, OConnell R, Lee Y, Joly F, Hilpert F, et al.
Gynecol Oncol . 2024 Feb; 185:128-137. PMID: 38412736
Objective: To describe the baseline symptom burden(SB) experienced by patients(pts) with recurrent ovarian cancer(ROC) prior and associations with progression free survival (PFS) and overall survival (OS). Methods: We analysed baseline...
2.
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Campbell R, Costa D, Stockler M, Lee Y, Ledermann J, Berton D, et al.
Gynecol Oncol . 2022 Jun; 166(2):254-262. PMID: 35718565
Purpose: The Measure of Ovarian Symptoms and Treatment (MOST) concerns is a validated patient-reported symptom assessment tool for assessing symptom benefit and adverse effects of palliative chemotherapy in women with...
3.
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)
Caminiti C, Bryce J, Riva S, Ng D, Diodati F, Iezzi E, et al.
Tumori . 2022 Jun; 109(3):324-334. PMID: 35674125
Introduction: US National Cancer Institute's (NCI) Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a library of 78 symptom terms and 124 items enabling patient...
4.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Lee Y, King M, OConnell R, Lanceley A, Joly F, Hilpert F, et al.
Int J Gynecol Cancer . 2022 Jan; 32(6):761-768. PMID: 35086926
Objective: The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum...
5.
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system
Riva S, Arenare L, Di Maio M, Efficace F, Montesarchio V, Frontini L, et al.
BMJ Open . 2021 Oct; 11(10):e049128. PMID: 34670762
Objectives: To measure and explain financial toxicity (FT) of cancer in Italy, where a public healthcare system exists and patients with cancer are not expected (or only marginally) to pay...
6.
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system
Riva S, Efficace F, Di Maio M, Bryce J, Del Campo L, De Lorenzo F, et al.
Support Care Cancer . 2020 Oct; 29(6):3219-3233. PMID: 33094357
Purpose: This paper illustrates a conceptual model for a new patient-reported outcome measure (PROM) aimed at measuring financial toxicity (FT) in oncological setting in Italy, where citizens are provided universal...
7.
Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol
Riva S, Bryce J, De Lorenzo F, Del Campo L, Di Maio M, Efficace F, et al.
BMJ Open . 2019 Sep; 9(9):e031485. PMID: 31501130
Introduction: Financial toxicity (FT) is a well-recognised problem in oncology. US-based studies have shown that: (a) cancer patients have a 2.7 times risk of bankruptcy; (b) patients who declare bankruptcy...
8.
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
King M, Stockler M, OConnell R, Buizen L, Joly F, Lanceley A, et al.
Qual Life Res . 2017 Dec; 27(1):59-74. PMID: 29248998
Purpose: Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST),...
9.
Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients
Capoluongo E, Ellison G, Lopez-Guerrero J, Penault-Llorca F, Ligtenberg M, Banerjee S, et al.
Semin Oncol . 2017 Dec; 44(3):187-197. PMID: 29248130
The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is...
10.
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Pignata S, Scambia G, Bologna A, Signoriello S, Vergote I, Wagner U, et al.
J Clin Oncol . 2017 Aug; 35(29):3347-3353. PMID: 28825853
Purpose Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective with a longer time interval from previous platinum treatment (platinum-free interval [PFI]). In 1999, it was...